Investigating the effects of a heart medication on hypertensive patients with different body weights
Effect of Sacubitril/Valsartan on Cardiac Function Assessed by Cardiac Magnetic Resonance (CMR) in Hypertensive Patients Stratified by Body Mass Index (BMI): A Real World Study
Beijing Friendship Hospital · NCT05498675
This study is testing how a heart medication called sacubitril/valsartan affects heart function in people with high blood pressure who have different body weights.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 180 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Beijing Friendship Hospital (other) |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05498675 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate how sacubitril/valsartan affects cardiac function in hypertensive patients, particularly focusing on differences based on body mass index (BMI). By utilizing cardiac magnetic resonance (CMR) imaging, the study will compare the cardiac structure and function of patients taking sacubitril/valsartan against those on other antihypertensive medications. The research seeks to clarify the potential benefits of this medication for various BMI groups in a real-world setting.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-70 with essential hypertension and no major barriers to providing consent.
Not a fit: Patients with secondary hypertension, recent cardiovascular events, or severe concomitant diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into personalized treatment strategies for hypertensive patients based on their BMI, potentially improving cardiac health outcomes.
How similar studies have performed: While there is existing research on sacubitril/valsartan, this specific focus on BMI stratification in hypertensive patients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with essential hypertension * 18-70 years old * No major barriers to provide written consent Exclusion Criteria: * Secondary hypertension, except because of sleep apnea * cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months * Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases) * Unable to understand or comply with the study procedures
Where this trial is running
Beijing, Beijing Municipality
- Beijing Friendship Hospital, Capital Medical University — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Principal investigator: Rongchong Huang, M.D. — Beijing Friendship Hospital
- Study coordinator: Rongchong Huang, M.D.
- Email: rchuang@ccmu.edu.cn
- Phone: +86-13811039417
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Sacubitril/Valsartan, Hypertension, Obesity, Cardiac function, Cardiac magnetic resonance